| The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. | |
| | |
MedLine Citation:
|
PMID: 18490196 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To examine whether hawthorn (Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients. METHODS: We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6 months. The primary outcome was time to progression of HF (HF death, hospitalisation, or sustained increase in diuretics) as assessed by log-rank tests and by Cox modelling. RESULTS: Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients receiving CSE were 3.9 times (95% CI=1.1-13.7: p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p=0.011). In patients with LVEF< or =35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p=0.02) than the placebo group. CONCLUSIONS: CSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF progression. |
| | |
Authors:
|
Suzanna M Zick; Brenda Gillespie; Keith D Aaronson |
Related Documents
:
|
11837516 - Plasma n-terminal pro-atrial natriuretic peptide predicts death after premature myocard... 19602906 - Genetic polymorphisms of hypoxia-inducible factor-1 alpha and cardiovascular disease in... 22977756 - Retrieval of a partially degloved stent strut during percutaneous coronary intervention. 22664146 - Association of matrix metalloproteinases (mmp2, mmp7 and mmp9) genetic variants with le... 10359926 - Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal ec... 15110206 - T-wave axis deviation as an independent predictor of mortality in chronic chagas' disease. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural Date: 2008-05-19 |
Journal Detail:
|
Title: European journal of heart failure Volume: 10 ISSN: 1388-9842 ISO Abbreviation: Eur. J. Heart Fail. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-06-09 Completed Date: 2008-11-18 Revised Date: 2011-06-08 |
Medline Journal Info:
|
Nlm Unique ID: 100887595 Medline TA: Eur J Heart Fail Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 587-93 Citation Subset: IM |
Affiliation:
|
Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA. szick@umich.edu <szick@umich.edu> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Crataegus Disease Progression Disease-Free Survival Double-Blind Method Female Follow-Up Studies Heart Failure / drug therapy*, mortality, physiopathology Humans Male Middle Aged Phytotherapy* Plant Extracts / therapeutic use* Retrospective Studies Severity of Illness Index Stroke Volume |
| Grant Support | |
ID/Acronym/Agency:
|
M01-RR00042/RR/NCRR NIH HHS; P50 HL 061202 01/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Plant Extracts; 8057-51-0/crataegus extract |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Human angiogenic cell precursors restore function in the infarcted rat heart: a comparison of cell d...
Next Document: The role of pegfilgrastim in mobilization of hematopoietic stem cells.